Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid ...
Editas Medicine and Genevant Sciences will collaborate to develop gene editing therapies, employing their respective CRISPR ...
Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to ...
and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences ...
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sci ...
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...
We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback